Ran Zhang, Author at MediaMedic

Dr. Peng Hu’s Team: “Gray Zone” Patients Have a Higher Risk of Disease Progression than HBeAg-Negative HBV Infections

By Ran Zhang 2024.02.27

Currently, there is limited research on the natural history of disease in patients with chronic hepatitis B in the "gray zone," and there is still debate about the necessity of…

Dr. Jun Li’s Team: ETS2 as a Potential New Target for the Diagnosis and Treatment of HBV-ACLF, Alleviating Liver Failure Progression by Suppressing Macrophage Immune Inflammatory Response

By Ran Zhang 2024.02.27

Hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) is a complex syndrome characterized by acute liver failure on the basis of chronic hepatitis B, triggered by various factors, with a short-term…

Dr. George-Lau: Advances and Reflections on Hepatitis B and Hepatitis D New Therapies

By Ran Zhang 2024.02.27

At the 58th European Association for the Study of the Liver (EASL) Annual Meeting (EASL2023) and the 2023 EASL Congress, one of the highlights was the emergence of new antiviral…

Dr. Zhang Huilai: Groundbreaking Research in Hodgkin Lymphoma

By Ran Zhang 2024.02.27

The 28th European Hematology Association (EHA) Congress took place from June 8 to 11, 2023, in Frankfurt, Germany, organized by the European Hematology Society. As one of the largest international…

Dr. Zhou Daobin: Exploring the Application of Sequential High-Dose Methotrexate in Newly Diagnosed Primary Central Nervous System Lymphoma Patients Without Chemotherapy

By Ran Zhang 2024.02.27

Editor's Note: Primary central nervous system lymphoma (PCNSL) is a relatively rare malignant tumor of the central nervous system, belonging to extranodal non-Hodgkin lymphoma. Due to factors such as the…

Posts by Ran Zhang

Dr. Peng Hu’s Team: “Gray Zone” Patients Have a Higher Risk of Disease Progression than HBeAg-Negative HBV Infections

Dr. Jun Li’s Team: ETS2 as a Potential New Target for the Diagnosis and Treatment of HBV-ACLF, Alleviating Liver Failure Progression by Suppressing Macrophage Immune Inflammatory Response

Dr. George-Lau: Advances and Reflections on Hepatitis B and Hepatitis D New Therapies

Dr. Zhang Huilai: Groundbreaking Research in Hodgkin Lymphoma

Dr. Zhou Daobin: Exploring the Application of Sequential High-Dose Methotrexate in Newly Diagnosed Primary Central Nervous System Lymphoma Patients Without Chemotherapy

CDL (co-management of diabetes-liver diseases strategy,) Literature Monthly Review – November 2023, Issue 10

Impact of Treatment Adjustments on the Prognosis of “T+A” Therapy in Unresectable Hepatocellular Carcinoma

Expert Insights | Dr. LechengYu: Is Mass Screening Necessary for HBV Infection in the General Population?

Striking Hard to Overcome the Final “Fortress” of Antiviral Treatment for Hepatitis C

Dr.JianWu: How to Prevent and Treat Overlooked “Hepatitis E”?